0.29635  0.014 (5.05%)		02-11 17:01
Open: 0.305 High: 0.323 Volume: 79,720		Pre. Close: 0.2821 Low: 0.28 Market Cap: 9(M)

Short term
Mid term
Targets	6-month :	0.61	1-year :	0.78
Resists	First :	0.52	Second :	0.67
Pivot price	0.37
Supports	First :	0.28	Second :	0.23
MAs	MA(5) :	0.3	MA(20) :	0.4
	MA(100) :	0.35	MA(250) :	1.27
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	5.5	D(3) :	5.3
RSI	RSI(14): 40
52-week	High :	3.75	Low :	0.2

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CTCX ] has closed above bottom band by 21.8%. Bollinger Bands are 5.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.32 - 0.32	0.32 - 0.33
Low:	0.28 - 0.28	0.28 - 0.28
Close:	0.3 - 0.3	0.3 - 0.3

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Fri, 24 Jan 2025
Carmell Therapeutics Announces Leadership Transition and New CEO - TipRanks

Thu, 02 Jan 2025
Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products - Yahoo Finance

Thu, 02 Jan 2025
Crude Oil Surges 2%; Tesla Shares Plummet - Jayud Global Logistics (NASDAQ:JYD), Carmell (NASDAQ:CTCX) - Benzinga

Thu, 02 Jan 2025
Carmell Acquires Elevai Skincare's $2.5M Revenue Portfolio, Expanding Bio-Aesthetic Platform - StockTitan

Thu, 02 Jan 2025
Carmell Therapeutics enters definitive agreement to acquire Elevai Skincare - TipRanks

Tue, 24 Dec 2024
Carmell Therapeutics Raises $1.85M in Private Placement with Potential $3.7M Total Funding - StockTitan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	30 (M)
Held by Insiders	1.299e+007 (%)
Held by Institutions	33.6 (%)
Shares Short	37 (K)
Shares Short P.Month	0 (K)

EPS	-4.93e+006
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-9 %
Return on Assets (ttm)	671.1 %
Return on Equity (ttm)	-84.7 %
Qtrly Rev. Growth	12320 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	38806.4
Qtrly Earnings Growth	0.4 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0.08

Dividend	0
Forward Dividend	505090
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.